Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia

Basit Öğe Kaydı
dc.authoridStefanadis, Christodoulos/0000-0001-5974-6454
dc.authoridkokacya, mehmet hanifi/0000-0002-2961-7229
dc.contributor.authorSahpolat, Musa
dc.contributor.authorAri, Mustafa
dc.contributor.authorKokacya, Mehmet Hanifi
dc.date.accessioned2024-09-18T20:25:08Z
dc.date.available2024-09-18T20:25:08Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: This study aims to investigate the possible relationship between plasma concentrations of apelin, visfatin and resistin levels of first episode psychosis patients and chronic schizophrenia patients. Methods: A total number of 29 untreated patients with first episode psychosis, 30 chronic schizophrenia and 29 randomly selected weight- and body mass index-matched healthy volunteers were included. The Diagnostic and Statistical Manual of Mental Disorders 4th edition, Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression Scale were applied to the patient groups. The enzyme-linked immunosorbent assay method was used to measure plasma apelin, visfatin and resistin levels. Results: There was no difference in age, marital status, occupation, and BMI between the groups. Plasma apelin levels were significantly higher in first episode psychosis group than chronic schizophrenia and control group. There was no statistically significant difference in plasma visfatin levels between the groups: first episode psychosis group, chronic schizophrenia and control group. Plasma resistin levels were higher in both first episode psychosis group and chronic schizophrenia group than the control group. There was no statistically significant correlation between plasma apelin and resistin levels and total PANSS scores in the group of patients. Conclusion: To our knowledge, this study is the first which investigates the plasma apelin, visfatin and resistin levels in patients with first episode psychosis and chronic schizophrenia. Based on the results of this study, apelin and resistin may be related with some central nervous system pathologies, including the severity of a psychiatric disorder.en_US
dc.identifier.doi10.9758/cpn.2020.18.1.109
dc.identifier.endpage115en_US
dc.identifier.issn1738-1088
dc.identifier.issn2093-4327
dc.identifier.issue1en_US
dc.identifier.pmid31958911en_US
dc.identifier.scopus2-s2.0-85084481762en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage109en_US
dc.identifier.urihttps://doi.org/10.9758/cpn.2020.18.1.109
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10090
dc.identifier.volume18en_US
dc.identifier.wosWOS:000508188800012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKorean Coll Neuropsychopharmacologyen_US
dc.relation.ispartofClinical Psychopharmacology and Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFirst episode psychosisen_US
dc.subjectSchizophreniaen_US
dc.subjectApelinen_US
dc.subjectNicotinamide phosphoribosyltransferaseen_US
dc.subjectResistinen_US
dc.titlePlasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophreniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu